<!DOCTYPE html>
<html>
  <head>
    <meta charset="utf-8">
    <title></title>
    <link rel="stylesheet" href="../../css/uswds.min.css">
    <link rel="stylesheet" href="../../css/style.css">
  </head>
  <body>

    <header>
        <h2 class="title">
            <a href="../../index.html">Code of Federal Regulations (alpha)</a>
        </h2>
    </header>

    <div class="usa-grid">
      <div class="usa-width-one-whole">
          <h3>
                                <a href="../../index.html">CFR</a><span>&nbsp/&nbsp</span>
                                <a href="../titles/title21.html">
                                    Title 21
                                </a><span>&nbsp/&nbsp</span>
                                <a href="../parts/21CFR310.html">Part 310
                                </a><span>&nbsp/&nbsp<span>
                                Sec. 310.200  Prescription-exemption procedure.
                            </h3>
                            <p class="depth1"><em>(a)</em> Duration of prescription requirement. Any drug limited to  prescription use under section 503(b)(1)(B) of the act remains so  limited until it is exempted as provided in paragraph (b) or (e) of this  section.</p><p class="depth1"><em>(b)(1)(B)</em> of the act  may be initiated by the Commissioner or by any interested person. Any  interested person may file a petition seeking such exemption, which  petition may be pursuant to part 10 of this chapter, or in the form of a  supplement to an approved new drug application.</p><p class="depth1"><em>(c)</em> New drug status of drugs exempted from the prescription  requirement. A drug exempted from the prescription requirement under the  provisions of paragraph (b) of this section is a ``new drug'' within the  meaning of section 201(p) of the act until it has been used   to a material extent and for a material time under such conditions  except as provided in paragraph (e) of this section.</p><p class="depth1"><em>(d)</em> Prescription legend not allowed on exempted drugs. The use of  the prescription caution statement quoted in section 503(b) (4) of the  act, in the labeling of a drug exempted under the provisions of this  section, constitutes misbranding. Any other statement or suggestion in  the labeling of a drug exempted under this section, that such drug is  limited to prescription use, may constitute misbranding.</p><p class="depth1"><em>(e)</em> Prescription-exemption procedure of OTC drug review. A drug  limited to prescription use under section 503(b)(1)(B) of the act may  also be exempted from prescription-dispensing requirements by the  procedure set forth in Sec. 330.13 of this chapter.  [39 FR 11680, Mar. 29, 1974, as amended at 41 FR 32582, Aug. 4, 1976; 42  FR 4714, Jan. 25, 1977; 42 FR 15674, Mar. 22, 1977; 72 FR 15043, Mar.  30, 2007]</p>
      </div>
    </div>

    <footer class="usa-footer usa-footer-slim" role="contentinfo">
    <div class="usa-grid usa-footer-return-to-top">
      <a href="#">Return to top</a>
    </div>
    <div class="usa-footer-primary-section">
      <div class="usa-grid-full">
        <h5>Built with ‚ù§ by <a href="https://18f.gsa.gov/">18F</a>.
          Code available <a href="https://github.com/18F/allregs">on Github.
        </a></h5>
        <h5>All regulations are from the 2015 Annual Edition.
          This is a technical demonstration not intended for serious use.</h5>
      </div>
    </div>
  </footer>
  </body>
</html>
